Myoblast fusion requires fibronectin degradation by exteriorized m-calpain.
We recently reported that when myoblasts fuse, m-calpain could be exteriorized. Indeed, at present a number of works support this hypothesis because this enzyme was localized intercellularly and more particularly associated to extracellular matrix components. Knowing that the cell surface of the fusing myoblast is supposed to undergo many changes, we addressed the question whether m-calpain could be involved in the phenomenon of fusion via fibronectin cleavage or degradation. Using different digestion experiments, we demonstrated that soluble purified fibronectin and highly insoluble fibronectin fibrils represent very good substrates for this proteinase; moreover, at the burst of fusion, fibronectin proteolytic fragments could be identified. On the other hand, we have conducted biological assays on cultured myoblasts using a defined medium supplemented by exogenous factors capable of stimulating or inhibiting m-calpain activity. The effects of such factors on rat myoblast fusion and concomitantly on the targeted glycoprotein were analyzed and quantified. When m-calpain activity and the phenomenon of fusion were reduced (defined medium without insulin), the amount of the 220-kDa fibronectin band was increased by 43%. When m-calpain activity and myoblast fusion were prevented by addition of antibodies to m-calpain or calpain inhibitor II, the fibronectin concentration was higher since it was increased by approximately 67 and approximately 71%, respectively. In addition, when observed at the ultrastructural level, m-calpain seems to be localized at the potential fusion site of myoblasts and more particularly associated to the extracellular matrix when muscle cells were initially treated by anti-m-calpain IgG. Taken together, these results support the hypothesis that exteriorized m-calpain could be, in part, involved in myoblast fusion via fibronectin alteration or degradation.
Dourdin
N
N
ENSSTAB, Laboratoire de Biochimie et Technologie des Aliments, Université de Bordeaux I and UA-INRA 429, Talence, France.
Brustis
J J
JJ
Balcerzak
D
D
Elamrani
N
N
Poussard
S
S
Cottin
P
P
Ducastaing
A
A
D000818:Animals; D002154:Calpain / Q000032:analysis / Q000037:antagonists & inhibitors / Q000378:metabolism*; D002459:Cell Fusion / Q000502:physiology*; D002478:Cells, Cultured; D015853:Cysteine Proteinase Inhibitors / Q000494:pharmacology; D005353:Fibronectins / Q000378:metabolism*; D007976:Leupeptins / Q000494:pharmacology; D018482:Muscle, Skeletal / Q000166:cytology* / Q000201:enzymology; D010446:Peptide Fragments / Q000032:analysis; D011480:Protease Inhibitors / Q000494:pharmacology; D011817:Rabbits; D051381:Rats; D017208:Rats, Wistar
D015853:Cysteine Proteinase Inhibitors; D005353:Fibronectins; D007976:Leupeptins; D010446:Peptide Fragments; D011480:Protease Inhibitors; D002154:Calpain; C032854:leupeptin